This suggests that ∆sVCAM-1 has utility in a subset of SLE patients where standard SLE biomarkers such as dsDNA antibody titre and complement C3/C4 levels fail to reflect disease activity. The gene discussed is C3; the disease is systemic lupus erythematosus.